NASDAQ:APVOAptevo Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aptevo Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.83 -0.12 (-2.02 %) (As of 06/4/2020 04:00 PM ET) Add Compare Share Today's Range$5.76Now: $5.83▼$6.0550-Day Range$3.66MA: $5.32▼$7.6552-Week Range$2.94Now: $5.83▼$14.56Volume27,507 shsAverage Volume95,307 shsMarket Capitalization$18.85 millionP/E RatioN/ADividend YieldN/ABeta2.71 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its investigational stage product candidates comprise APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome; APVO210, an anti-inflammatory molecule that is in pre-clinical development stage for the treatment of autoimmune and inflammatory diseases; ALG.APV-527, a bispecific antibody to target T cells; ROR1 Bispecific, a proof-of-concept bispecific candidate that is in preclinical development; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAptevo Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.75, Aptevo Therapeutics has a potential upside of 84.4% from its current price of $5.83.Amount of Analyst CoverageAptevo Therapeutics has received no research coverage in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesAptevo Therapeutics has received 179 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAptevo Therapeutics has received 194 “underperform” votes. (Add your “underperform” vote.)Community SentimentAptevo Therapeutics has received 52.01% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aptevo Therapeutics and other stocks. Vote “Outperform” if you believe APVO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe APVO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAptevo Therapeutics does not currently pay a dividend.Dividend GrowthAptevo Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aptevo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 10.88% of the stock of Aptevo Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 15.78% of the stock of Aptevo Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aptevo Therapeutics are expected to grow in the coming year, from ($13.61) to ($8.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aptevo Therapeutics is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aptevo Therapeutics is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAptevo Therapeutics has a P/B Ratio of 1.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.31 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APVO Previous Symbol CUSIPN/A CIK1671584 Webwww.aptevotherapeutics.com Phone206-838-0500Debt Debt-to-Equity Ratio0.20 Current Ratio2.12 Quick Ratio2.12Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$32.42 million Price / Sales0.58 Cash FlowN/A Price / Cash FlowN/A Book Value$3.66 per share Price / Book1.59Profitability EPS (Most Recent Fiscal Year)($15.27) Net Income$-40,450,000.00 Net Margins-102.54% Return on Equity-224.05% Return on Assets-79.58%Miscellaneous Employees118 Outstanding Shares3,233,000Market Cap$18.85 million Next Earnings Date8/14/2020 (Estimated) OptionableOptionable NASDAQ:APVO Rates by TradingView Receive APVO News and Ratings via Email Sign-up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter. Aptevo Therapeutics (NASDAQ:APVO) Frequently Asked Questions How has Aptevo Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Aptevo Therapeutics' stock was trading at $0.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, APVO stock has increased by 1,288.1% and is now trading at $5.83. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Aptevo Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aptevo Therapeutics. When is Aptevo Therapeutics' next earnings date? Aptevo Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Aptevo Therapeutics. How were Aptevo Therapeutics' earnings last quarter? Aptevo Therapeutics Inc (NASDAQ:APVO) issued its earnings results on Wednesday, May, 13th. The biotechnology company reported ($2.84) EPS for the quarter, missing analysts' consensus estimates of ($2.35) by $0.49. Aptevo Therapeutics had a negative return on equity of 224.05% and a negative net margin of 102.54%. View Aptevo Therapeutics' earnings history. What price target have analysts set for APVO? 1 equities research analysts have issued 1-year price targets for Aptevo Therapeutics' shares. Their forecasts range from $3.00 to $18.50. On average, they anticipate Aptevo Therapeutics' stock price to reach $10.75 in the next year. This suggests a possible upside of 84.4% from the stock's current price. View analysts' price targets for Aptevo Therapeutics. Has Aptevo Therapeutics been receiving favorable news coverage? News headlines about APVO stock have been trending negative on Friday, according to InfoTrie. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aptevo Therapeutics earned a news sentiment score of -2.7 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutAptevo Therapeutics. Are investors shorting Aptevo Therapeutics? Aptevo Therapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 53,000 shares, a decline of 8.5% from the April 30th total of 57,900 shares. Based on an average trading volume of 120,500 shares, the days-to-cover ratio is currently 0.4 days. Approximately 1.8% of the company's stock are sold short. View Aptevo Therapeutics' Current Options Chain. Who are some of Aptevo Therapeutics' key competitors? Some companies that are related to Aptevo Therapeutics include CV Sciences (CVSI), Elite Pharmaceuticals (ELTP), Proteostasis Therapeutics (PTI), Alpine Immune Sciences (ALPN), Enlivex Therapeutics (ENLV), DiaMedica Therapeutics (DMAC), Stealth BioTherapeutics (MITO), Moleculin Biotech (MBRX), Capricor Therapeutics (CAPR), Heat Biologics (HTBX), CannTrust (CNTTF), Trevi Therapeutics (TRVI), VERONA PHARMA P/S (VRNA), Aridis Pharmaceuticals (ARDS) and Vaccinex (VCNX). View all competitors. What other stocks do shareholders of Aptevo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Amarin (AMRN), Axsome Therapeutics (AXSM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and Netflix (NFLX). Who are Aptevo Therapeutics' key executives? Aptevo Therapeutics' management team includes the following people: Mr. Marvin L. White, Pres, CEO & Director (Age 57)Mr. Jeffrey G. Lamothe, Sr. VP, CFO & Treasurer (Age 53)Dr. Scott C. Stromatt, Sr. VP of Clinical Devel. & Medical Affairs and Chief Medical Officer (Age 61)Mr. Randy Joe Maddux, Sr. VP of Operations & Chief Manufacturing Officer (Age 58)Dr. Jane A. Gross, Sr. VP & Chief Scientific Officer (Age 62) What is Aptevo Therapeutics' stock symbol? Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO." Who are Aptevo Therapeutics' major shareholders? Aptevo Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (0.68%) and UBS Group AG (0.36%). Company insiders that own Aptevo Therapeutics stock include Barbara Lopez Kunz, Daniel Abdun-Nabi, Fuad El-Hibri, Grady Grant III, Marvin L White, Randy Joe Maddux and Zsolt Harsanyi. View institutional ownership trends for Aptevo Therapeutics. Which major investors are selling Aptevo Therapeutics stock? APVO stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., and UBS Group AG. View insider buying and selling activity for Aptevo Therapeutics. How do I buy shares of Aptevo Therapeutics? Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Aptevo Therapeutics' stock price today? One share of APVO stock can currently be purchased for approximately $5.83. How big of a company is Aptevo Therapeutics? Aptevo Therapeutics has a market capitalization of $18.85 million and generates $32.42 million in revenue each year. The biotechnology company earns $-40,450,000.00 in net income (profit) each year or ($15.27) on an earnings per share basis. Aptevo Therapeutics employs 118 workers across the globe. What is Aptevo Therapeutics' official website? The official website for Aptevo Therapeutics is www.aptevotherapeutics.com. How can I contact Aptevo Therapeutics? Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at 206-838-0500 or via email at [email protected] This page was last updated on 6/5/2020 by MarketBeat.com Staff
